Strategies for Neuroprotection, Relapse Prevention, and Mortality Reduction in Patients with Schizophrenia

Target Audience

This education activity is directed towards OB-GYNs, medical oncologists, surgical oncologists, radiation oncologists, primary care physicians, such as family practitioners and internists, and radiologists.

Program Overview

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma and is a distinct entity from systemic ALCL. In the United States, the FDA began to recognize reports of ALCL and a potential association with breast implants in 2011, and subsequently started a collaboration with the American Society of Plastic Surgeons (ASPS) and the Plastic Surgery Foundation (PSF) to create the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and Epidemiology (PROFILE Registry). Incidence has been associated with the textured surface of the implant and is highest in the more highly textured (ie, greater surface area) implants. Reports indicate that the majority of cases, if diagnosed quickly, are limited to effusion around the implant and can frequently be effectively treated with surgical intervention without the need for adjuvant systemic therapy. However, given the recent history of BIA-ALCL and the infrequency of incidence, physicians who see patients at first presentation of disease are unlikely to be familiar with symptoms.

This Community Practice Connection™ program is designed to assist clinicians in keeping up to date on developments in the recently defined malignancy BIA-ALCL. This online program will provide a comprehensive review of BIA-ALCL, including epidemiology, presentation, diagnosis, and treatment strategies. Integrated expert video interviews will highlight the practical application of recent data that directly influence treatment guidelines and best practices to help you provide optimal care to your patients.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

Describe presenting symptoms of BIA-ALCL and how to distinguish this cancer from other breast implant problems
Discuss the incidence and prevalence of BIA-ALCL and the need for centralized reporting
Identify best practices in BIA-ALCL treatment and discuss evidence available for treatment options
Detail a treatment strategy that incorporates a multidisciplinary team to optimize outcomes for patients with BIA-ALCL